Scholar Rock Holding Corp (SRRK): Total Assets
$404.27M
As of 2025-12-31
$523.54M
As of 2026-06-30
+4.1%
3-year compound annual growth
+0.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $404.27M | -14.9% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $474.92M | +52.7% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $311.04M | -13.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $358.17M | +17.6% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $304.44M | -21.6% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $388.31M | +97.7% | 2022-03-07, Balance as of period end |
| 2019-12-31 | $196.38M | +8.3% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $181.34M | +194.2% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $61.64M | n/a | 2019-03-19, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $404.27M | -14.9% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare SRRK, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗